COMPARATIVE ANALYSIS OF PULMONARY HYPERTENSION IN THE 105 CML PATIENTS TREATED WITH IMATINIB, NILOTINIB AND DASATINIB

被引：0
|
作者：
Minami, M. [1 ]
Miyamoto, T. [1 ]
Akashi, K. [1 ]
机构：
[1] Kyushu Univ, Dept Med & Biosyst Sci, Fukuoka, Japan
来源：
HAEMATOLOGICA | 2017年 / 102卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PB1816
引用
收藏
页码：728 / 728
页数：1
相关论文
共 50 条
  • [41] Report on imatinib treated CML patients: Pregnancy outcome
    Dasgupta, S.
    Mukhopadhyay, A.
    Ray, U. K.
    Gharami, F. H.
    Basu, C. K.
    Mukhopadhyay, S.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S844 - S844
  • [42] REAL-LIFE COMPARISON OF DASATINIB AND NILOTINIB AS SECOND-LINE THERAPY AFTER IMATINIB FAILURE FOR CHRONIC PHASE CML
    Tiribelli, M.
    Bonifacio, M.
    Binotto, G.
    Iurlo, A.
    Cibien, F.
    Maino, E.
    Guella, A.
    Festini, G.
    Minotto, C.
    De Biasi, E.
    De Marchi, F.
    Scaffidi, L.
    Frison, L.
    Bucelli, C.
    Medeot, M.
    Calistri, E.
    Sancetta, R.
    Stulle, M.
    Krampera, M.
    Gherlinzoni, F.
    Semenzato, G.
    Ambrosetti, A.
    Fanin, R.
    HAEMATOLOGICA, 2016, 101 : 237 - 238
  • [43] The hOCT1 substrate metformin does not alter imatinib, dasatinib or nilotinib uptake into CML cells at clinically relevant concentrations
    Francis, S.
    Giannoudis, A.
    Pirmohamed, M.
    Clark, R. E.
    BRITISH JOURNAL OF HAEMATOLOGY, 2013, 161 : 58 - 59
  • [44] Prior Response to Imatinib Predicts Response to Second Line Treatment with Nilotinib in CML Patients Resistant or Intolerant to Imatinib
    Koren-Michowitz, Maya
    le Coutre, Philipp D.
    Duyster, Justus
    Scheid, Christof
    Panayiotidis, Panayiotis
    Prejzner, Witold
    Rowe, Jacob M.
    Schwarz, Michaela
    Goldschmidt, Neta
    Nagler, Arnon
    BLOOD, 2009, 114 (22) : 1278 - 1278
  • [45] Nilotinib after resistance to imatinib in CML patients with Wolf-Parkinson White syndrome
    Breccia, Massimo
    CLINICAL MANAGEMENT ISSUES, 2010, 4 : 7 - 11
  • [46] Nilotinib Exposure-Response Analysis In Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia (CML)
    Giles, Francis J.
    Yin, Ophelia
    Chia, Yen Lin
    le Coutre, Philipp D.
    Woodman, Richard C.
    Ottmann, Oliver G.
    Baccarani, Michele
    Kantarjian, Hagop M.
    BLOOD, 2010, 116 (21) : 390 - 390
  • [47] THE ECONOMIC BURDEN OF DASATINIB AND NILOTINIB TREATMENT FAILURE IN CHRONIC MYELOID LEUKEMIA (CML) PATIENTS: A REAL-WORLD ANALYSIS
    Pokras, S. M.
    Divino, V
    Ferrufino, C. P.
    Arnold, R. J. G.
    Huang, H.
    VALUE IN HEALTH, 2013, 16 (03) : A137 - A137
  • [48] Prognostic Impact of Deletions of Derivative Chromosome 9 on Patients (PTS) with Chronic Myelogenous Leukemia (CML) in Chronic Phase Treated with Nilotinib or Dasatinib
    Quintas-Cardama, Alfonso
    Kantarjian, Hagop M.
    O'Brien, Susan
    Borthakur, Gautam
    Verstovsek, Srdan
    Wierda, William
    Shan, Jenny
    Cortes, Jorge
    BLOOD, 2008, 112 (11) : 734 - 735
  • [49] ECONOMIC EVALUATION OF DASATINIB IN CHRONIC MYELOGENOUS LEUKAEMIA PATIENTS RESISTANT TO IMATINIB IN PERU, COMPARED TO NILOTINIB AND HIGH DOSES OF IMATINIB
    Orozco Giraldo, J. J.
    Valencia, J. E.
    Garrido Lecca, S.
    Aiello, E. C.
    VALUE IN HEALTH, 2011, 14 (03) : A168 - A168
  • [50] Prognostic impact of deletions of derivative chromosome 9 on patients (pts) with chronic myelogenous leukemia (CML) in chronic phase treated with nilotinib or dasatinib
    Quintas-Cardama, Alfonso
    Kantarjian, Hagop
    Thomas, Deborah
    Koller, Charles
    Shan, Jenny
    Cortes, Jorge
    BLOOD, 2007, 110 (11) : 581A - 581A
12345